Cutaneous T-cell lymphoma: practical recommendations to enhance clinical practice

Area of Science:

• Oncology
• Dermatology
• Hematology

Background:

• Cutaneous T-cell lymphoma (CTCL) management necessitates a comprehensive strategy addressing patient wellbeing.
• Treatment efficacy and goals vary significantly between early and advanced stages of the disease.

Purpose of the Study:

• To outline current management principles for cutaneous T-cell lymphoma (CTCL) based on disease stage.
• To highlight the importance of a holistic and multidisciplinary approach in optimizing patient outcomes and quality of life.

Main Methods:

• Review of national and international guidelines for stage-related treatment options in CTCL.
• Discussion of first-line and second-line therapeutic strategies, including skin-directed treatments and systemic therapies.
• Consideration of recent European Medicines Agency approvals and existing unmet needs in CTCL treatment.

Main Results:

• Early-stage CTCL patients often have a near-normal life expectancy with management focused on symptom relief and minimal adverse effects.
• Advanced-stage CTCL requires a multidisciplinary approach to prevent progression, prolong life, and manage debilitating symptoms.
• Recent drug approvals offer new options, yet a significant unmet need for improved treatments and cures persists.

Conclusions:

• CTCL management is tailored to disease stage, prioritizing skin-directed therapies and symptom control for early stages.
• Advanced CTCL demands a multidisciplinary strategy, with allogeneic stem cell transplant as a potential option for eligible patients.
• Despite therapeutic advances, achieving complete responses and cures remains challenging, underscoring the need for further research and development.